Overview

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2011-08-01

Target enrollment:

Participant gender:

Summary

The purpose of the study was to compare Humalog (insulin lispro)-recombinant human hyaluronidase PH20 (rHuPH20) or Novolog (insulin aspart)-rHuPH20 to insulin lispro for the treatment of Type 2 diabetes mellitus (T2DM) in basal-bolus therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Halozyme Therapeutics

Treatments:

Insulin
Insulin Aspart
Insulin Glargine
Insulin glulisine
Insulin Lispro
Insulin, Globin Zinc